Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Implementing antibody-drug conjugates (ADCs) in HER2+ BC

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Dec 01, 2021 1:01pm

296 Views

Post# 34185685

Implementing antibody-drug conjugates (ADCs) in HER2+ BC

Ongoing challenges with ADCs include improving target specificity, optimizing the toxicity profile, and identifying biomarkers for patient selection.

ONCY has been addressing the above challenges through pelareorep's clinical development plan that includes the AWARE-1 WOO study.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record